arrow_back Back Filing freshness 10-Q FY 2028 SEC EDGAR

download Export Data

TuHURA Biosciences, Inc./NV

HURA

$1.61 ▼ -0.11 (-6.40%) at close

10 Visible periods

21 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, TuHURA Biosciences, Inc./NV shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $207.3M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC —

FCF / Share $-0.05 ↗

Trailing P/E 25.5x

Price / Book 105.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$8.05M

↓ -27.7% —

FCF / Share Free cash flow per share

$-0.05

↑ +48.0% —

Long-Term Debt Long-term obligations

$1.12K

↓ -96.0% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of -0.79x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2028 Jun 30, 2019 10-K ↗	FY 2027 Jun 30, 2018 10-K ↗	FY 2026 Jun 30, 2017 10-K ↗	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Jun 30, 2023 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Jun 30, 2021 10-K ↗	FY 2019 Jun 30, 2020 10-K ↗
EPS Growth YoY (%)	-41.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-26.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	47.9% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	51.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	73.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	64.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-80525.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-83.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	-27.7% Weak ↓ Weak Declining Year-over-year change in net income	37.8% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	-38.6% Weak ↓ Weak Declining Year-over-year change in net income	26.0% Excellent ↑ Excellent Improving Year-over-year change in net income	-100.1% Weak ↓ Weak Declining Year-over-year change in net income	35.4% Excellent ↑ Excellent Improving Year-over-year change in net income	40.8% Excellent Excellent Year-over-year change in net income	-319.7% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	48.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	29.1% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	77.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	27.0% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	21.7% Good ↑ Good Improving Year-over-year change in free cash flow	86.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	65.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-143579.3% Weak Weak Year-over-year change in free cash flow	4.0% Caution Caution Year-over-year change in free cash flow	—

💰 Are margins durable? 2 metrics

Metric	FY 2028 Jun 30, 2019 10-K ↗	FY 2027 Jun 30, 2018 10-K ↗	FY 2026 Jun 30, 2017 10-K ↗	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Jun 30, 2023 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Jun 30, 2021 10-K ↗	FY 2019 Jun 30, 2020 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
FCF / Net Income (x)	-0.79x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.88x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.99x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 1 metrics

Metric	FY 2028 Jun 30, 2019 10-K ↗	FY 2027 Jun 30, 2018 10-K ↗	FY 2026 Jun 30, 2017 10-K ↗	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Jun 30, 2023 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Jun 30, 2021 10-K ↗	FY 2019 Jun 30, 2020 10-K ↗
Return on Common Equity (%) (%)	—	204.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1266%)	122.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+719%)	-143.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1057%)	-148.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1090%)	—	—	-192.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1381%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2028 Jun 30, 2019 10-K ↗	FY 2027 Jun 30, 2018 10-K ↗	FY 2026 Jun 30, 2017 10-K ↗	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Jun 30, 2023 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Jun 30, 2021 10-K ↗	FY 2019 Jun 30, 2020 10-K ↗
Debt to Equity (x)	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	—	—	—	—	—	—	—
Net Debt (USD)	$-3.72M	$-5.97M	$-6.56M	$-3.62M	$-12.66M	$-3.67M	$-1.53M	$-11.78M	$-10.54M	$-2.39M

📊 What does each share earn? 6 metrics

Metric	FY 2028 Jun 30, 2019 10-K ↗	FY 2027 Jun 30, 2018 10-K ↗	FY 2026 Jun 30, 2017 10-K ↗	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Jun 30, 2023 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Jun 30, 2021 10-K ↗	FY 2019 Jun 30, 2020 10-K ↗
Revenue per Share (USD)	—	—	—	$0.00	$0.00	$0.00	—	—	—	—
Basic EPS, GAAP (USD)	$0.06	$0.11	$0.15	$-0.63	$-1.21	$-2.47	$-9.27	$-25.80	$-0.03	$-0.02
Free Cash Flow per Share (USD)	$-0.05	$-0.09	$-0.13	$-0.58	$-0.79	$-1.01	$-7.32	$-20.94	$-0.01	$-0.02
Book Value per Share (USD)	$0.02	$0.05	$1.34	$0.35	$0.35	$-0.13	$0.45	$12.11	$0.01	$0.00
Tangible Book Value per Share (USD)	$0.02	$0.05	$1.34	$0.17	$0.35	$-0.13	$0.45	$12.11	$0.01	$0.00
Basic Weighted Avg Shares (shares)	128.73M	104.31M	60.24M	47.93M	18.66M	11.89M	1.62M	974,000	1.29B	522.20M

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2028 Jun 30, 2019 10-K ↗	FY 2027 Jun 30, 2018 10-K ↗	FY 2026 Jun 30, 2017 10-K ↗	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Jun 30, 2023 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Jun 30, 2021 10-K ↗	FY 2019 Jun 30, 2020 10-K ↗
Working Capital (USD)	$1.96M	$5.41M	$6.57M	$-1.30M	$14.28M	$562.42K	$188.00K	$9.27M	$9.01M	$176.00K
LT Debt (USD)	—	$1.12K	$28.14K	—	—	—	—	—	—	—
Total Equity (USD)	$1.97M	$5.44M	$6.58M	$20.93M	$14.59M	$-1.56M	$731.00K	$11.79M	$10.58M	$263.00K

📋 What is driving earnings? 4 metrics

Metric	FY 2028 Jun 30, 2019 10-K ↗	FY 2027 Jun 30, 2018 10-K ↗	FY 2026 Jun 30, 2017 10-K ↗	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Jun 30, 2023 10-K ↗	FY 2021 Jun 30, 2022 10-K ↗	FY 2020 Jun 30, 2021 10-K ↗	FY 2019 Jun 30, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$0.00	$0.00	$0.00	—	—	—	—
Depreciation Expense (USD)	—	—	—	$71.27K	$116.71K	$177.38K	$60.00K	$60.00K	$30.00K	—
Net Income, GAAP (USD)	$8.05M	$11.14M	$8.08M	$-30.05M	$-21.68M	$-29.32M	$-14.65M	$-22.66M	$-38.30M	$-9.13M
Operating Cash Flow (USD)	$-6.33M	$-9.85M	$-8.02M	$-27.63M	$-14.73M	$-11.95M	$-11.87M	$-20.39M	$-18.86M	$-7.93M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 10 years · 53 quarters

TuHURA Biosciences, Inc./NV

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare HURA with peers